Published • loading... • Updated
AstraZeneca's Breast Cancer Drug Fails in Late-Stage Trial
The 1,371-patient SERENA-4 study found only a numerical benefit, raising questions about the drug’s first-line role despite recent accelerated approval.
- On Friday, AstraZeneca announced that Etcamah failed its late-stage trial for first-line advanced breast cancer treatment, missing the primary progression-free survival goal just one week after gaining separate approval.
- The SERENA-4 trial enrolled 1,371 patients with ER-positive, HER2-negative advanced breast cancer to test the combination of Etcamah and Pfizer's Ibrance against standard hormone-lowering treatments.
- AstraZeneca's drug showed only numerical, not statistically significant, improvement in progression-free survival, mirroring a similar failure by Swiss drugmaker Roche in newly diagnosed patients earlier this month.
- US-Listed shares of AstraZeneca fell 3% following the announcement, though Barclays analyst James Gordon described the update as "well anticipated by the market" given Roche's prior failure.
- RBC Capital analyst Trung Huynh called the results a "manageable setback" that clears near-term uncertainty, as Jefferies reports peak annual sales potential of more than $5 billion remains largely intact.
Insights by Ground AI
12 Articles
12 Articles
Compared to the standard treatment, the drug could not stop the progression of the disease more strongly. The result could dampen the optimism for the drug.
·Düsseldorf, Germany
Read Full Article
The Economic TimesReposted by 
Times of India
Times of IndiaAstraZeneca's breast cancer drug fails in late-stage trial
AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.
·Mumbai, India
Read Full Article
Coverage Details
Total News Sources12
Leaning Left0Leaning Right6Center5Last UpdatedBias Distribution55% Right
Bias Distribution
- 55% of the sources lean Right
55% Right
C 45%
R 55%
Factuality
To view factuality data please Upgrade to Premium
